Prediction of infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: development of a clinical decision-making nomogram

References

• Datta N, Kontomichalou P. Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. Nature. 1965;208:239–241.
   PubMed Web of Science ®Google Scholar
• Knothe H, Shah P, Krcmery V, et al. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 1983;11:315–317.
   PubMed Web of Science ®Google Scholar
• Baquero F, Reguera JA, Ojeda M, et al. Escherichia coli con resistencia a cefalosporina de 3a generación codificada por beta-lactamasas de tipo plasmídico: primer brote en España. Rev Esp Microbiol Clin. 1988;3:581–582.
   Google Scholar
• Mirelis B, Navarro F, Miro E, et al. Community transmission of extended-spectrum beta-lactamase. Emerging Infect Dis. 2003;9:1024–1025.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob. Agents Chemother. 2007;51:1987–1994.
   PubMed Web of Science ®Google Scholar
• Schwaber M, Carmeli Y. Mortality delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60:913–920.
   PubMed Web of Science ®Google Scholar
• Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128–140.
   PubMed Web of Science ®Google Scholar
• Friedman ND, Daye KS, Stout JE, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definitions of community-acquired bacteremia. Ann Intern Med. 2002;137:791–797.
   PubMed Web of Science ®Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing. Break points tables for interpretation of MICs and zone diameters. Version 6.0. European Society of Clinical Microbiology and Infectious Diseases. 2016. Available from: http://www.eucast.org
   Google Scholar
• Bochicchio GV, Baquero F, Hsueh PR, et al. In vitro susceptibilities of Escherichia coli isolated from patients with intra-abdominal infections worldwide in 2002-2004: results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Surg Infect (Larchmt). 2006;7:537–545.
   PubMedGoogle Scholar
• Reinert RR, Low DE, Rossi F, et al. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother. 2007;60:1018–1029.
   PubMed Web of Science ®Google Scholar
• Arana D, Rubio M, Alos JI. Evolution of antibiotic multiresistance in Escherichia coli and Klebsiella pneumoniae isolates from urinary tract infections: a 12-year analysis (2003-2014). Enferm Infecc Microbiol Clin. 2017;35:293–298.
   PubMed Web of Science ®Google Scholar
• Andreu A, Planells I. Grupo Cooperativo Español para el Estudio de la Sensibillidad Antimicrobiana de los Patógenos Urinarios. Etiology of community-acquired lower urinary infections and antimicrobial resistance of Escherichia coli: a national surveillance study. Med Clin (Barc). 2008;130:481–486.
   PubMed Web of Science ®Google Scholar
• Goossens H. MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis. 2001;41:183–189.
   PubMed Web of Science ®Google Scholar
• Lee DS, Lee CB, Lee SJ. Prevalence and risk factors for extended spectrum beta-lactamase-producing uropathogens in patients with urinary tract infection. Korean J Urol. 2010;51:492–497.
   PubMedGoogle Scholar
• Ena J, Arjona F, Martínez-Peinado C. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Urology. 2006;68:1169–1174.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Alcalá JC, Cisneros JM, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 2008;168:1897–1902.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Baño J, Navarro MD, Romero L, et al. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis. 2006;42:37–45.
   PubMed Web of Science ®Google Scholar
• Colodner R, Rock W, Chazan B, et al. Risk factors for the development of extended-spectrum beta-latamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004;23:163–167.
   PubMed Web of Science ®Google Scholar
• Peña C, Gudiol C, Tubau F, et al. Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients. Clin Microbiol Infect. 2006;12:279–284.
   PubMed Web of Science ®Google Scholar
• Hoban DJ, Nicolle LE, Hawser S, et al. Antimicrobial susceptibility of global inpatient rinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010. Diagn Microbiol Infect Dis. 2011;70:507–511.
   PubMed Web of Science ®Google Scholar
• Saltoglu N, Karali R, Yemisen M, et al. Comparison of community-onset healthcare-associated and hospital acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities. Int J Clin Pract. 2015;69:766–770.
   PubMed Web of Science ®Google Scholar
• Grundmann H, Livermore DM, Giske CG, et al. Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill. 2010;15:19711.
   PubMedGoogle Scholar
• Azap OK, Arslan H, Serefhanoglu K. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect. 2010;16:147–151.
   PubMed Web of Science ®Google Scholar
• Garau J. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect.2008;14(Suppl):198–202.
   Web of Science ®Google Scholar
• Hernández MS, García JA, Muñoz JL. In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin. Rev Esp Quimioter. 2009;22:25–29.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kastoris AC, Kapaskelis AM, et al. Fosfomycin for the treatment of multidrug-reistant, including extended-spectrum beta-lactamase producing, Enteriobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10:43–50.
   PubMed Web of Science ®Google Scholar
• Oteo J, Bautista V, Lara N, et al. Parallel increase in community use of fosfomycin and resistance to fofomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother. 2010;65:2459–2463.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Avial C, Rodríguez-Avial I, Hernández E, et al. Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005-2009-2011. Rev Esp Quimioter. 2013;26:43–46.
   PubMed Web of Science ®Google Scholar
• García-Tello A, Gimbernat H, Redondo C, Arana DM, et al. Extended-spectrum beta-lactamases in urinary tract infections caused by Enterobacteria: understanding and guidelines for action. Actas Urol Esp. 2014;38:678–684.
   PubMed Web of Science ®Google Scholar